from Breakingviews:

Abbott’s $25 bln buy inspires little investor hope

April 28, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant plays chicken with death spiral

March 15, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Financial Regulatory Forum:

Potential Supreme Court tie on Obamacare contraceptives could snarl health insurers

March 14, 2016

By Michael Blissenbach, Regulatory Intelligence

(Thomson Reuters Regulatory Intelligence) - The U.S. Supreme Court on March 23 will hear arguments in a major Obamacare case over insurance and contraception, with a range of potential outcomes that became more complicated with the death of Justice Antonin Scalia.

from Breakingviews:

Alere board’s diligence brings 51 pct premium

February 1, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Financial Regulatory Forum:

IMPACT ANALYSIS: Second phase audits of patient-privacy compliance starting under U.S. health agency

January 26, 2016

By Elizabeth Polking, Regulatory Intelligence

(Thomson Reuters Regulatory Intelligence) - Hundreds of U.S. health-care providers over the next three years will be scrutinized for their compliance with patient privacy regulations, as regulators respond to findings of widespread compliance gaps and launch a new round of industry audits.

from Breakingviews:

Healthcare M&A will wear down in 2016

January 4, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Financial Regulatory Forum:

COMMENTARY: Insurance mergers face U.S. regulatory uncertainty despite inversions clarification

December 28, 2015

By Lawrence Hsieh, Practical Law

Although the pharmaceutical industry has drawn a lot of the attention given to corporate inversions, the regulatory environment for these tax-saving corporate relocation transactions also affects insurance mergers.

from Breakingviews:

Theranos’ wounded credibility hobbles all unicorns

December 21, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Sanofi and Boehringer scratch each others’ backs

December 15, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pfizer’s $150 bln plan is high-risk, low-benefit

November 19, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.